#USA #ITF Therapeutics #Erica Monaco #DUVYZAT #Concord

ITF Therapeutics Appoints New COO

ITF Therapeutics LLC, based in Concord, Massachusetts, recently announced that Erica L. Monaco, CPA, has been appointed as the new Chief Operating Officer. The appointment is set against a backdrop of significant achievements for the company, including the U.S. FDA approval and successful launch of their innovative drug, DUVYZAT™ (givinostat), specifically for treating Duchenne muscular dystrophy (DMD).

A Leader with Extensive Experience

Erica brings nearly two decades of invaluable experience from both the pharmaceutical and financial sectors. Prior to joining ITF Therapeutics, she held crucial leadership roles, most notably as the COO at Medicus Pharma Ltd. Her rich background also includes positions like CEO, CFO, and COO at Biofrontera Inc., where she played a pivotal role in securing funding and guiding the company through its IPO.

During her impressive career, Erica helped build the U.S. infrastructure necessary for the launch of treatments for actinic keratosis, demonstrating her ability to manage complex operational needs and compliance in high-stakes environments. Starting her journey in public accounting and financial planning, she has worked with reputable firms like Deloitte and has made her mark in senior roles at SUN Pharmaceuticals, overseeing key financial and reporting functions.

Vision for ITF Therapeutics

Matt Trudeau, President of ITF Therapeutics, expressed great enthusiasm for Erica's appointment. He noted that her comprehensive financial and operational acumen will be instrumental in enhancing the company’s efficiency and adherence to regulations, especially as it continues its commitment to serving rare disease communities. Since its establishment in January 2024, ITF Therapeutics has focused on assembling a dedicated team of experts passionate about making a difference in the lives of those affected by rare diseases.

Erica shared her excitement, stating, “I am thrilled to join ITF Therapeutics at this pivotal time. It is an honor to work with an exceptional team dedicated to addressing the operational requirements we face today and gearing up for future growth.”

About DUVYZAT™

DUVYZAT, an HDAC (histone deacetylase) inhibitor, has been developed to help manage DMD, a severe genetic condition affecting muscle strength and function. By mitigating the overactivity of HDAC enzymes that contribute to chronic inflammation and muscle degeneration, DUVYZAT aims to enhance muscle repair and ultimately slow the progression of this debilitating disease.

The collaboration between ITF Therapeutics, Italfarmaco, Telethon, and Duchenne Parent Project has been fundamental in bringing this treatment to market, showcasing the power of partnerships in addressing unmet medical needs.

ITF Therapeutics' Mission

Launched as the U.S. affiliate of Italfarmaco, ITF Therapeutics is keen on innovating and commercializing therapies for rare diseases. The company emphasizes collaboration with patient advocacy organizations to align their programs with the distinct requirements of those they serve. Grounded in a legacy of innovation and teamwork, ITF aims to influence positively the lives of rare disease patients, propelled by the expertise and commitment of its newly appointed COO and the dedicated team.

For more information about ITF Therapeutics and DUVYZAT, visit www.itftherapeutics.com or www.DUVYZAT.com.